Novel triple neurokinin receptor antagonist CS-003 inhibits respiratory disease models in guinea pigs.
Neurokinins are known to induce neurogenic inflammation related to respiratory diseases. The effects of CS-003 ([1-{2-[(2R)-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl}spiro[benzo[c]thiophene-1(3H),4'-piperidine]-(2S)-oxide hydrochloride]), a novel triple neurokinin receptor antagonist, on several respiratory disease models were evaluated in guinea pigs. As we have already shown that CS-003 is intravenously effective, we first determined if CS-003 was orally effective. CS-003 dose-dependently inhibited substance P-induced tracheal vascular hyperpermeability, neurokinin A- and neurokinin B-induced bronchoconstriction with ID(50) values of 3.6, 1.3 and 0.89 mg/kg (p.o.), respectively. CS-003 (10 mg/kg, p.o.) inhibited the number of coughs induced by capsaicin aerosol (P<0.01) and the antitussive effect was comparable to that of codeine. CS-003 (10 mg/kg, p.o.) also inhibited airway hyperresponsiveness to methacholine chloride in ovalbumin-induced asthma models (P<0.01), a milder one and a severer one. On the other hand, montelukast (10 mg/kg, p.o.), a leukotriene receptor antagonist, significantly inhibited the hyperresponsiveness only in the milder model (P<0.05). In an ovalbumin-induced rhinitis model, oral administration of CS-003 inhibited nasal blockade in a dose-dependent manner and the inhibitory effect was comparable to that of dexamethasone (10 mg/kg, p.o.). CS-003 (i.v.) also dose-dependently inhibited cigarette smoke-induced bronchoconstriction, tracheal vascular hyperpermeability and mucus secretion. These data show that CS-003, a potent orally active triple neurokinin receptor antagonist, may be useful for the treatment of respiratory diseases associated with neurokinins, such as allergic asthma, allergic rhinitis, chronic obstructive pulmonary disease and cough.
Tsuchida
Hiroshi
H
Biological Research Laboratories III, DAIICHI SANKYO CO., LTD., 1-16-13 Kitakasai, Edogawa-ku, Tokyo, Japan.
Takahashi
Sakiko
S
Nosaka
Emi
E
Kuraya
Takako
T
Yamashita
Makoto
M
Morimoto
Kiyoshi
K
D000284:Administration, Oral; D000818:Animals; D001249:Asthma / Q000188:drug therapy / Q000276:immunology; D016084:Bronchoconstriction / Q000187:drug effects; D002199:Capillary Permeability / Q000187:drug effects; D002211:Capsaicin; D003371:Cough / Q000139:chemically induced / Q000188:drug therapy; D003499:Cyclic S-Oxides / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D006168:Guinea Pigs; D008297:Male; D009025:Morpholines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D009093:Mucus / Q000378:metabolism; D010047:Ovalbumin; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy; D018039:Receptors, Tachykinin / Q000037:antagonists & inhibitors*; D012140:Respiratory Tract Diseases / Q000188:drug therapy*; D012220:Rhinitis / Q000188:drug therapy / Q000276:immunology; D012906:Smoke; D014026:Nicotiana; D014132:Trachea / Q000098:blood supply / Q000378:metabolism
C530698:1-(2-(2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl)ethyl)spiro(benzo(c)thiophene-1(3H),4'-piperidine)-2-oxide; D003499:Cyclic S-Oxides; D009025:Morpholines; D018039:Receptors, Tachykinin; D012906:Smoke; D010047:Ovalbumin; D002211:Capsaicin